Alonso-Pérez C, Alcántara-Salinas A, Escobar-Rojas V, Ramírez-Sandoval MP, Reyes-Hernández MU, Guerrero-Becerra M, Vargas-Mosso ME, Hernández-Magaña R, Anzures-Gutiérrez SA, Cuevas-López LL, Comas-García A, Reyes-Hernández KL, Reyes-Gómez U

Language: Spanish
References: 20
Page: 88-101
PDF size: 280.98 Kb.

ABSTRACT

Campylobacter is a small Gram negative bacillus, within this genus are Helicobacter and Arcobacter. It is a cause of intestinal infection in humans. Campylobacter infection is usually mild and self-limited, it is usually self-limiting in immunocompetent patients, but in patients with some morbidity it can have complications and endanger life. Guillain-Barre syndrome continues to be a frequent complication even in patients without previous morbidity. Maintaining adequate hydration and electrolyte correction should be the focus of therapy. Antibiotics are not needed for most cases of Campylobacter gastroenteritis. Primary prevention measures that mainly include a simple way to avoid the disease.

REFERENCES

1. Allos B. Microbiology, pathogenesis, and epidemiology of Campylobacter infection. En: Calderwood S, ed. UpToDate. Waltham, Mass.: UpToDate; 2017 (acceso 11 de abril del 2019). Disponible en: https:// www.uptodate.com/contents/microbiology-patogenesis- and-epidemiology-of-campylobacter-infection.

2. Van den A, Vogelaers D, Van Hende J. Houf K. Prevalence of Arcobacter species among humans. Belgium, 2008-2013. Emerg Infect Dis. 2014; 20: 1731-34.

3. Seo TH, Lee SY, Uchida T, Fujioka T, Jin CJ, Hwang TS, et al. The origin of non-H. pylori-related positive Giemsa staining in human gastric biopsy specimens: A prospective study. Dig Liver Dis. 2011; 43: 23-7.

4. Lastovica AJ, Allos BM. Clinical significance of Campylobacter and related species other than Campylobacter jejuni and Campylobacter coli. En: Nachamkin I, Szymanski CM, Blaser MJ, editores. Campylobacter. 3a. ed., Washington, DC: American Society for Microbiology; 2008. p.123.

5. Allos B. Clinical manifestations, diagnosis, and treatment of Campylobacter infection. En: Bloom A, editor. UpToDate. Waltham, Mass.: UpToDate; 2017 (acceso 11 de abril de 2019). Disponible en: https://www.uptodate.com/contents/clinical-manifestations- diagnosis-and-traetment-of-campylobacter- infection

6. Centers for Disease Control and Prevention (CDC). Incidence and trends of infection with pathogens transmitted commonly through food - foodborne diseases active surveillance network, 10 U.S. sites, 1996-2012. MMWR Morb Mortal Wkly Rep. 2013; 62: 283-7.

7. Longenberger AH, Palumbo AJ, Chu AK, Moll ME, Weltman A, Ostroff SM. Campylobacter jejuni infections associated with unpasteurized milk--multiple States, 2012. Clin Infect Dis. 2013; 57: 263-6.

8. Gaudreau C, Rodrigues-Coutlée S, Pilon PA, Coutlée F, Bekal S. Long-Lasting Outbreak of Erythromycinand Ciprofloxacin-Resistant Campylobacter jejuni Subspecies jejuni From 2003 to 2013 in Men Who Have Sex With Men, Quebec, Canada. Clin Infect Dis. 2015; 61: 1549-52.

9. Hernández C, Aguilera A, Castro E. Campylobacter jejuni: ¿una bacteria olvidada? Situación en México. Enf Inf Microbiol. 2013; 33(2): 77-84.

10. Fitzgerald C, Patrick M, González A, Akin J, Polage CR, et al . Multicenter Evaluation of Clinical Diagnostic Methods for Detection and Isolation of Campylobacter spp. from Stool. J Clin Microbiol. 2016; 54: 1209-15.

11. LaRocque R, Harris B. Travelers´diarrhea: Clinical manifestations, diagnosis, and treatment. En: Bloom A, editor. UpToDate. Waltham, Mass.: UpToDate; 2018 (acceso 11 de abril de 2019). Disponible en: https://www.uptodate.com/contents/travelers-diarrhea- clinical-manifestations-diagnosis-and-treatment

12. Ugarte RM, Gómez BS, Porrero MC et al. Evaluation of four protocols for the detection and isolation of thermophilic Campylobacter from different matrices. J Appl Microbiol. 2012; 113: 200-8.

13. European Center for Disease Prevention and Control [sede Web]. Annual epidemiologic report: Campybacteriosis [Internet]; 2016 (acceso 25 de abril de 2018). Disponible en: http://ecdc.europea.eu/en/ healthtopics/campylobacteriosis/surveillance-data/ Pages/Annual-surveillance-data.aspc

14. Ryan M. Guillain-Barré syndrome in children: Epidemiology; clinical features, and diagnosis. En: Dashe F, editor. UpToDate. Waltham, Mass.: UpToDate; 2017 (acceso 11 de abril de 2019). Disponible en: ht tps://www.uptodate.com/contents/guillain-barre-syndrome- in-children-epidemiology-clinical-features- and-diagnosis

15. Vriesendorp J. Guillain-Barré syndrome: Pathogenesis. En: Eichler F, editor. UpToDate. Waltham, Mass.: UpToDate; 2018 (acceso 11 de abril de 2019). Disponible en: https://www.uptodate.com/contents/ guillain-barre-syndrome-pathogenesis

16. Moore S. Persistent diarrhea in children in resource- limited countries. En: Hoppin G, editor. UpToDate. Waltham, Mass.: UpToDate; 2017 (acceso 11 de abril de 2019). Disponible en: https://www.uptodate. com/contents/persistent-diarrhea-in-children-in-resource- limited-countries

17. Geissler AL, Bustos Carrillo F, Swanson K et al. Increasing Campylobacter Infections, Outbreaks, and Antimicrobial Resistance in the United States, 2004- 2012. YClin Infect Dis. 2017; 65: 1624-31.

18. Patrick ME, Gilbert JM, Blaser MJ, Tauxe RV, Wagenaar JA, Fitzgerald C. Human infections with new subspecies of Campylobacter fetus. Emerg Infect Dis. 2013; 19: 1678-80.

19. Persson S, Petersen HM, Jespersgaard C, Olsen KE. Real-time taxman polymerase chain reaction-based genus-identification and pyrosequencing-based species identification of Campylobacter jejuni, C. coli, C. lari, C. upsaliensis, and C. fetus directly on stool samples. Diagn Microbiol Infect Dis. 2012; 74: 6-12.

20. Ternhag A, AsikainenT, Giesecke J. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis. 2007; 44: 696-8.